Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy

ACS Nano

Volumn 7, Issue 11, 2013, Pages 9896-9904

  Guo, Shutao ^a   Wang, Yuhua ^a   Miao, Lei ^a   Xu, Zhenghong ^a   Lin, C Michael ^a   Zhang, Yuan ^a   Huang, Leaf ^a  

^a University of North Carolina   (United States)

Author keywords

chemotherapy; cisplatin; drug delivery; nanomedicine; neighboring effect

Indexed keywords

ANTI-TUMOR EFFICACY; CIS-PLATIN; ENCAPSULATION EFFICIENCY; FUNCTIONAL PARAMETERS; HIGH DRUG LOADINGS; NEIGHBORING EFFECT; REVERSE MICROEMULSION METHOD; THERAPEUTIC POTENTIALS;

CELL DEATH; CHEMOTHERAPY; DERMATOLOGY; DRUG DELIVERY; DRUG PRODUCTS; ENCAPSULATION; MEDICAL NANOTECHNOLOGY; MICROEMULSIONS; NANOPARTICLES; ONCOLOGY; PLATINUM COMPOUNDS; SOLUBILITY; TUMORS;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; BIOMATERIAL; CISPLATIN; DRUG CARRIER; GREEN FLUORESCENT PROTEIN; LIPID; NANOPARTICLE;

ANIMAL; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CHEMISTRY; DIFFUSION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; IC 50; LIVER; METABOLISM; METHODOLOGY; MOUSE; NANOMEDICINE; NUDE MOUSE; PATHOLOGY; SOLUBILITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; COATED MATERIALS, BIOCOMPATIBLE; DIFFUSION; DRUG CARRIERS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LIPIDS; LIVER; MICE; MICE, NUDE; NANOMEDICINE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; SOLUBILITY;

EID: 84888876456     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn403606m     Document Type: Article

References (28)

1. Rosenber., B.; Vancamp, L.; Krigas, T. Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode Nature 1965, 205, 698-699
2. Lebwohl, D.; Canetta, R. Clinical Development of Platinum Complexes in Cancer Therapy: An Historical Perspective and an Update Eur. J. Cancer 1998, 34, 1522-1534 (Pubitemid 28446332)
3. Drayton, R. M.; Catto, J. W. F. Molecular Mechanisms of Cisplatin Resistance in Bladder Cancer Expert Rev. Anticancer Ther. 2012, 12, 271-281
4. Liang, X. J.; Meng, H.; Wang, Y.; He, H.; Meng, J.; Lu, J.; Wang, P. C.; Zhao, Y.; Gao, X.; Sun, B. et al. Metallofullerene Nanoparticles Circumvent Tumor Resistance to Cisplatin by Reactivating Endocytosis Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 7449-7454
5. Go, R. S.; Adjei, A. A. Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin J. Clin. Oncol. 1999, 17, 409-422 (Pubitemid 29022420)
6. Farokhzad, O. C.; Langer, R. Nanomedicine: Developing Smarter Therapeutic and Diagnostic Modalities Adv. Drug Delivery Rev. 2006, 58, 1456-1459 (Pubitemid 44820502)
7. Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
8. Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes FEBS Lett. 1990, 268, 235-237 (Pubitemid 20233874)
9. Farokhzad, O. C.; Karp, J. M.; Langer, R. Nanoparticle-Aptamer Bioconjugates for Cancer Targeting Expert Opin. Drug Delivery 2006, 3, 311-324 (Pubitemid 43772708)
10. Banerjee, R.; Tyagi, P.; Li, S.; Huang, L. Anisamide-Targeted Stealth Liposomes: A Potent Carrier for Targeting Doxorubicin to Human Prostate Cancer Cells Int. J. Cancer 2004, 112, 693-700 (Pubitemid 39425952)
11. Li, Z.; Huang, P.; Zhang, X.; Lin, J.; Yang, S.; Liu, B.; Gao, F.; Xi, P.; Ren, Q.; Cui, D. Rgd-Conjugated Dendrimer-Modified Gold Nanorods for in Vivo Tumor Targeting and Photothermal Therapy Mol. Pharmaceutics 2009, 7, 94-104
12. Zhang, C. F.; Jugold, M.; Woenne, E. C.; Lammers, T.; Morgenstern, B.; Mueller, M. M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W. et al. Specific Targeting of Tumor Angiogenesis by Rgd-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 1.5-T Magnetic Resonance Scanner Cancer Res. 2007, 67, 1555-1562 (Pubitemid 46383379)
13. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor Vascular Permeability and the Epr Effect in Macromolecular Therapeutics: A Review J. Controlled Release 2000, 65, 271-284 (Pubitemid 30122932)
14. Cabral, H.; Matsumoto, Y.; Mizuno, K.; Chen, Q.; Murakami, M.; Kimura, M.; Terada, Y.; Kano, M. R.; Miyazono, K.; Uesaka, M. et al. Accumulation of Sub-100 Nm Polymeric Micelles in Poorly Permeable Tumours Depends on Size Nat. Nano 2011, 6, 815-823
15. Chauhan, V. P.; Stylianopoulos, T.; Martin, J. D.; Popović, Z.; Chen, O.; Kamoun, W. S.; Bawendi, M. G.; Fukumura, D.; Jain, R. K. Normalization of Tumour Blood Vessels Improves the Delivery of Nanomedicines in a Size-Dependent Manner Nat. Nanotechnol. 2012, 7, 383-388
16. Burger, K. N.; Staffhorst, R. W.; de Vijlder, H. C.; Velinova, M. J.; Bomans, P. H.; Frederik, P. M.; de Kruijff, B. Nanocapsules: Lipid-Coated Aggregates of Cisplatin with High Cytotoxicity Nat. Med. 2002, 8, 81-84 (Pubitemid 34101733)
17. Hamelers, I. H.; de Kroon, A. I. Nanocapsules: A Novel Lipid Formulation Platform for Platinum-Based Anti-Cancer Drugs J. Liposome Res. 2007, 17, 183-189 (Pubitemid 350133588)
18. Khiati, S.; Luvino, D.; Oumzil, K.; Chauffert, B.; Camplo, M.; Barthelemy, P. Nucleoside-Lipid-Based Nanoparticles for Cisplatin Delivery ACS Nano 2011, 5, 8649-8655
19. Kieler-Ferguson, H. M.; Fréchet, J. M. J.; Szoka, F. C., Jr Clinical Developments of Chemotherapeutic Nanomedicines: Polymers and Liposomes for Delivery of Camptothecins and Platinum (Ii) Drugs Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2013, 5, 130-138
20. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted Delivery of Cisplatin to Prostate Cancer Cells by Aptamer Functionalized Pt(IV) Prodrug-Plga-Peg Nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 17356-17361
21. Li, X.; Wang, L.-K.; Wang, L.-W.; Han, X.-Q.; Yang, F.; Gong, Z.-J. Cisplatin Protects against Acute Liver Failure by Inhibiting Nuclear Hmgb1 Release Int. J. Mol. Sci. 2013, 14, 11224-11237
22. Basu, A.; Krishnamurthy, S., Cellular Responses to Cisplatin-Induced DNA Damage. J. Nucleic Acids 2010, 2010.
23. Kang, T.-H.; Lindsey-Boltz, L. A.; Reardon, J. T.; Sancar, A. Circadian Control of Xpa and Excision Repair of Cisplatin-DNA Damage by Cryptochrome and Herc2 Ubiquitin Ligase Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 4890-4895
24. Newman, M. S.; Colbern, G. T.; Working, P. K.; Engbers, C.; Amantea, M. A. Comparative Pharmacokinetics, Tissue Distribution, and Therapeutic Effectiveness of Cisplatin Encapsulated in Long-Circulating, Pegylated Liposomes (Spi-077) in Tumor-Bearing Mice Cancer Chemother. Pharmacol. 1999, 43, 1-7 (Pubitemid 29048341)
25. Comenge, J.; Sotelo, C.; Romero, F.; Gallego, O.; Barnadas, A.; Parada, T. G.-C.; Domínguez, F.; Puntes, V. F. Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin PLoS One 2012, 7, e47562
26. Guo, S.; Miao, L.; Wang, Y.; Huang, L. Unmodified Drug Used as a Material to Construct Nanoparticles: Delivery of Cisplatin for Enhanced Anti-Cancer Therapy. J. Controlled Release 2013, submitted for publication.
27. Graf, N.; Bielenberg, D. R.; Kolishetti, N.; Muus, C.; Banyard, J.; Farokhzad, O. C.; Lippard, S. J. Alpha(V)Beta(3) Integrin-Targeted Plga-Peg Nanoparticles for Enhanced Anti-Tumor Efficacy of a Pt(Iv) Prodrug ACS Nano 2012, 6, 4530-4539
28. Mcgahan, M. C.; Tyczkowska, K. The Determination of Platinum in Biological-Materials by Electrothermal Atomic-Absorption Spectroscopy Spectrochim. Acta, Part B 1987, 42, 665-668